Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities

• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention

Genomics plc, a pioneering healthcare company that uses large-scale genetic information to develop innovative precision healthcare tools, is pleased to announce that it has successfully completed a $30m funding round. Some highlights include:
· Follows achievement of significant milestones in both its Precision Health and Therapeutics division
· Significant investment from leading life science investors Foresite Capital and F-Prime Capital
· Existing backers Oxford Sciences Innovation and Lansdowne Partners also participated
· Fundraise was oversubscribed
Genomics plc will use the funding to expand its work building a patient-centric, population health platform that unlocks a more proactive, precise and personalised form of healthcare.

Daniel Vogel joins Genomics plc as Chief Financial Officer, adding international commercial and financial expertise.

Genomics plc strengthens leadership team with the addition of Mitchell Harris as Chief Strategy Officer and Professor Gil McVean as Chief Information Officer.

The UK has a major opportunity to transform the health and care system to a “Prevention First” model by using new genomic technology.

Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities

• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention

Genomics plc, a pioneering healthcare company that uses large-scale genetic information to develop innovative precision healthcare tools, is pleased to announce that it has successfully completed a $30m funding round. Some highlights include:
· Follows achievement of significant milestones in both its Precision Health and Therapeutics division
· Significant investment from leading life science investors Foresite Capital and F-Prime Capital
· Existing backers Oxford Sciences Innovation and Lansdowne Partners also participated
· Fundraise was oversubscribed
Genomics plc will use the funding to expand its work building a patient-centric, population health platform that unlocks a more proactive, precise and personalised form of healthcare.

Daniel Vogel joins Genomics plc as Chief Financial Officer, adding international commercial and financial expertise.

Genomics plc strengthens leadership team with the addition of Mitchell Harris as Chief Strategy Officer and Professor Gil McVean as Chief Information Officer.

The UK has a major opportunity to transform the health and care system to a “Prevention First” model by using new genomic technology.

Companies confirm a two-year extension of their collaboration using genomics and machine learning to identify novel targets for innovative medicines and accelerate drug discovery

• Polygenic risk scores (PRS) substantially enhance risk prediction in cardiovascular disease (CVD), the #1 cause of death around the world
• These study results represent the first clinical validation of such a tool across multiple ancestries and ethnicities

• Genomics plc’s method outperforms current tools and could help save more than 2,000 lives annually in the US alone
• Opportunity to identify individuals who are at risk of heart disease and target immediate prevention

Genomics plc, a pioneering healthcare company that uses large-scale genetic information to develop innovative precision healthcare tools, is pleased to announce that it has successfully completed a $30m funding round. Some highlights include:
· Follows achievement of significant milestones in both its Precision Health and Therapeutics division
· Significant investment from leading life science investors Foresite Capital and F-Prime Capital
· Existing backers Oxford Sciences Innovation and Lansdowne Partners also participated
· Fundraise was oversubscribed
Genomics plc will use the funding to expand its work building a patient-centric, population health platform that unlocks a more proactive, precise and personalised form of healthcare.

Daniel Vogel joins Genomics plc as Chief Financial Officer, adding international commercial and financial expertise.

Genomics plc strengthens leadership team with the addition of Mitchell Harris as Chief Strategy Officer and Professor Gil McVean as Chief Information Officer.

The UK has a major opportunity to transform the health and care system to a “Prevention First” model by using new genomic technology.